Report of the WHO technical consultation on the evaluation of respiratory syncytial virus prevention cost effectiveness in low- and middle-income countries, April 7–8, 2022

• DOI: 10.1016/j.vaccine.2023.09.040
• Publication Date: 2023-09-28T21:25:49Z
• Authors: Meagan C. Fitzpat...; Rachel S. Laufer; Ranju Baral; Amanda J. Driscoll; Daniel R. Feikin; Jessica A. Fleming; Mark Jit; Sonnie Kim; Mihaly Koltai; You Li; Xiao Li; Harish Nair; Kathleen M. Neuzil; Clint Pecenka; Erin Sparrow; Padmini Srikantiah; Justin R. Ortiz
• Keywords: Economic Evaluation; Cost database

Policymakers often rely on impact and cost-effectiveness evaluations to inform decisions about the introduction of health interventions in low- middle-income countries (LMICs); however, results for same intervention can differ by choice parameter inputs, modelling assumptions, geography. Anticipating near-term availability new respiratory syncytial virus (RSV) prevention products, WHO convened a two-day virtual consultation April 2022 with stakeholder groups global experts economics, epidemiology, vaccine implementation. The objective was review methods, parameterization, existing analyses RSV LMICs; identify most influential inputs data limitations; recommend prioritize future gathering research improve estimates LMICs. Epidemiological parameters identified as both uncertain were those associated hospitalization death, specifically setting-specific rates RSV-attributable death rates. Influential economic included product price, delivery costs, willingness-to-pay part potential donors, cost RSV-associated hospitalization. Some at this meeting should be more precisely measured further research. Other that are highly may not resolved, it is appropriate use sensitivity explore these within evaluations. This report highlights presentations major discussions meeting.